Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.
You may also be interested in...
After shutting down its trial for a leukemia conditioning agent due to a patient death, Magenta’s review of strategic alternatives concludes with a combination with complement inhibitor-focused Dianthus.
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
German TCR developer in partnerships with GSK and BMS will go public and receive $252m at closing in a reverse merger-type transaction with Arya.